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Cimp-positive status is More 
Representative in Multiple 
Colorectal Cancers than in Unique 
primary Colorectal Cancers
sandra tapial1,2, Susana olmedillas-López3, Daniel Rueda1,2, María Arriba  4, 
Juan L. García5,6, Alfredo Vivas7, Jessica pérez5,6, Laura pena-Couso8, Rocío olivera3, 
Yolanda Rodríguez9, Mariano García-Arranz3, Damián García-Olmo  3,10,  
Rogelio González-Sarmiento5,6, Miguel Urioste8,11, Ajay Goel12 & José perea  10
Colorectal cancer (CRC) with CpG island methylator phenotype (CIMP) is recognized as a subgroup 
of CRC that shows association with particular genetic defects and patient outcomes. We analyzed 
CIMP status of 229 individuals with CRC using an eight-marker panel (CACNA1G, CDKN2A, CRABP1, 
IGF2, MLH1, NEUROG1, RUNX3 and SOCS1); CIMp-(+) tumors were defined as having ≥ 5 methylated 
markers. Patients were divided into individuals who developed a “unique” CRC, which were 
subclassified into early-onset CRC (EOCRC) and late-onset CRC (LOCRC), and patients with multiple 
primary CRCs subclassified into synchronous CRC (SCRC) and metachronous CRC (MCRC). We found 9 
(15.2%) CIMP-(+) eoCRC patients related with the proximal colon (p = 0.008), and 19 (26.8%) CIMP-
(+) LOCRC patients associated with tumor differentiation (p = 0.045), MSI status (p = 0.021) and 
BRAF mutation (p = 0.001). Thirty-five (64.8%) SCRC patients had at least one CIMP-(+) tumor and 
20 (44.4%) MCRC patients presented their first tumor as CIMP-(+). Thirty-nine (72.2%) SCRC patients 
showed concordant CIMP status in their simultaneous tumors. The differences in CIMP-(+) frequency 
between groups may reflect the importance of taking into account several criteria for the development 
of multiple primary neoplasms. Additionally, the concordance between synchronous tumors suggests 
CIMP status is generally maintained in SCRC patients.
Colorectal cancer (CRC) is one of the most frequent malignancies representing the second cause of mortality related 
to cancer, moreover its incidence continues to rise gradually1. Growing evidence suggests that CRC is a heterogene-
ous disorder that can develop through different pathways involving distinct combinations of genetic and epigenetic 
alterations. Specific phenotypes are derived from these alterations which result in different prognosis and disease 
evolution2,3. Consequently, a better knowledge of the molecular events involved in the appearance and progression 
of CRC could provide new insight into therapeutic targets and markers for risk stratification4. Currently, three main 
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pathways are widely accepted to be involved in the etiology of CRC: Chromosomal Instability (CIN), Microsatellite 
Instability (MSI) and CpG Island Methylator Phenotype (CIMP)5–7. Structural rearrangements as well as gains and 
losses of chromosome fragments are characteristic features of CIN tumors, possibly associated with higher mutation 
rates; the majority of sporadic cases are in this group8. MSI is associated with changes in short microsatellite repeats, 
caused by deficient mismatch repair (MMR) genes, and is related to hereditary non-polyposis colorectal cancer 
(HNPCC), also called Lynch Syndrome (LS), and some sporadic cases in the elderly population9. Lastly, tumor sup-
pressor and DNA repair genes are frequently transcriptionally silenced in CIMP cases. Furthermore, several studies 
have shown that CIMP positivity is associated with proximal colon location, presence of mucinous features, poor 
tumor differentiation, MSI, female gender and high BRAF mutation rates10,11.
Genetic, biological and clinical differences have been identified depending on the age of onset of CRC in many 
studies, thus it has been suggested that CRC should be subclassified attending this major criterion12–15. There 
are other features that should also be taken into account for subclassification, such as the development of two or 
more different tumors because these cases provide a good model to examine “field effect”. This effect is associ-
ated with the tendency of healthy colorectal mucosa to suffer early molecular alterations that trigger malignant 
transformation of the tissue16,17. Synchronous CRC (SCRC) is defined by the presence of more than one tumor 
simultaneously, while metachronous CRC (MCRC) is characterized by the development of a second lesion after 
surgery and/or diagnosis of the primary tumor18–20.
Given the above, when focusing on CIMP status, it is important to take the type of CRC, into consideration, 
since CIMP status affects the response to therapy21,22 and it may have a relation to the “field effect” linked to 
CRC23,24. For this reason, we examined CIMP status in different CRC subtypes: patients with a single tumor 
(“unique” CRC), divided into early-onset CRC (EOCRC; age at diagnosis ≤ 45 years old) and patients with 
late-onset CRC (LOCRC; age at diagnosis > 70 years old); and individuals diagnosed with multiple primary CRC, 
i.e. patients diagnosed with SCRC or MCRC.
Methods
patients. A total of 229 CRC patients were included in this study at 12 de Octubre Hospital (Madrid, Spain). 
Among these patients (all of them Caucasian), 59 had EOCRC, 71 had LOCRC, 54 were diagnosed with SCRC 
and 45 were diagnosed with MCRC. SCRC was diagnosed when two or more histologically different lesions were 
developed simultaneously or within a time lapse shorter than six months after the detection of the first tumor19. 
When a secondary neoplasm was detected outside the anastomosis area after more than 6 months of the initial 
tumor diagnosis, it was considered as MCRC25. Samples with the highest content of tumor tissue were selected 
for molecular analysis. A multi-site database was used to collect clinicopathological, therapeutic and pre- and 
post-operative information. Informed consent was signed by all patients or by a first degree relative when the 
patient had died. The protocol of this study was approved by the Ethics Committee of this Institution.
DNA isolation. Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples were selected by a pathologist. To 
be suitable for molecular analysis, one sample should contain a minimum percentage of 70% tumor cells. Briefly, DNA 
was extracted from FFPE samples using mineral oil to dissolve the paraffin, followed by proteinase K digestion and eth-
anol precipitation. DNA was further purified and eluted using CLART® HPV2 kit (Genomica S.A.U., Madrid, Spain).
Microsatellite analysis and analysis of BRAF mutation, hypermethylation of MLH1 and 
germline mutations in MMR genes. Microsatellite instability status of each tumor was defined using 
the Bethesda five-marker microsatellite panel (NR-21, BAT-26, BAT-25, NR-24 and MONO-27)26. Fluorescence 
labeled primers were included for amplification of markers, then the PCR products were separated using capillary 
electrophoresis and analyzed. When 2 or more markers showed instability, the sample was defined as micro-
satellite instable (Fig. 1). Moreover, MSI tumors were analyzed for the BRAFV600E mutation and hypermethyla-
tion of the MLH1 gene promoter in order to verify their sporadic nature, using methylation-specific multiplex 
ligation-dependent probe amplification (MS-MLPA; ME011-B3, ME0042-CIMP, MRC-Holland, Amsterdam, 
The Netherlands). MSI cases also were screened for Lynch Syndrome by evaluating germline mutations in the 
MMR genes (MLH1, MSH2 and MSH6) by high-resolution melting analysis using a LightCycler 480 real-time 
PCR system (Roche, Mannheim, Germany), as previously reported27.
KRAs mutations. Mutations in KRAS (codons 12, 13 and 61) were determined previously in patients younger 
than 45 and older than 70 years. Briefly, DNA was extracted from the neoplastic material, and Sanger sequencing 
was carried out in both orientations on a 3130 DNA Analyzer (Applied Biosystems, Foster City, CA, USA)28. The 
genetic alterations of KRAS in individuals diagnosed with SCRC and MCRC were evaluated by next generation 
sequencing using a gene panel related to cancer (Ion PGM System, ThermoFisher, Waltham, MA, USA) (Fig. 2).
CpG island methylator phenotype analysis. For the evaluation of CIMP, we examined the methylation 
status of the promoter regions of CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1 
using the SALSA MS-MLPA Probemix (ME0042-CIMP, MRC-Holland, Amsterdam, The Netherlands). Each 
patient was classified as CIMP-(+) or CIMP-(−) depending on whether tumors showed ≥ 5/8 or < 5/8 methyl-
ated promoters, respectively (Fig. 3A,B)11. Patients diagnosed with multiple CRC and distinct CIMP statuses in 
their tumors were categorized as CIMP-MM (mismatching).
statistical analysis. Clinical characteristics were compared between different groups according to CIMP 
status, including age, sex, stage, tumor location, presence of mucinous features, BRAF and KRAS mutations, and 
MSI status. Categorical variables were expressed as number of cases and their percentage, and continuous varia-
bles were expressed as mean values plus/minus standard deviation (SD). Comparison of categorical variables was 
done using Pearson’s Chi Square (X2) test. For comparisons between two groups Student’s t test was performed, 
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and for comparisons between more than two groups analysis of variance (ANOVA) (for normal distributions) 
or the Kruskal-Wallis test (for nonparametric distributions) were used. Statistical analysis was carried out using 
IBM SPSS 17.0 (SPSS Inc., Chicago, IL, USA). P value of <0.05 was considered statistically significant differences.
ethics approval and consent to participate. Study approval was obtained from the Ethics Committee of 
the 12 de Octubre University Hospital in Madrid, Spain. All procedures were performed in accordance with the 
ethical standards of the institutional research committee and the Declaration of Helsinki.
Results
Global features of “unique” colorectal cancer. We collected clinical characteristics of 130 individuals 
with “unique” CRC, of which 59 were EOCRC cases and the remaining 71 patients were LOCRC cases. The aver-
age age at diagnosis was 40 ± 5 and 78 ± 6 years old for EOCRC and LOCRC, respectively. Male to female ratio 
was >1 in the EOCRC group, whereas in the LOCRC set it was < 1. When we assessed the anatomical location of 
the tumors, the EOCRC group showed most tumors (47.5%) at the distal colon, while LOCRC patients presented 
more rectum location (42.3%). Among the 59 patients with EOCRC, 8 (13.6%) patients showed MSI status, of 
Figure 1. Sample showing Microsatellite stability (above) and other showing Microsatellite instability (below).
Figure 2. Sample with wild-type KRAS (above), other sample with codon 13 mutation (medium), and the last 
with codon 12 mutation (below), seen in the Integrative Genomics Viewer by Next Generation Sequencing.
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which 3 (37.5%) were sporadic cases: 1 (12.5%) presented a BRAF mutation and 2 (25.0%) showed hypermeth-
ylation of the MLH1 gene promoter; the remaining 5 (62.5%) individuals were diagnosed with LS. Moreover, 22 
(40.7%) EOCRC patients had a KRAS mutation. In the LOCRC group, 6 (8.5%) patients showed MSI status, all 
of them sporadic cases, 6 (8.5%) patients had a BRAF mutation and 1 (16.7%) case presented a KRAS mutation 
(Tables 1 and 2).
Global features of primary multiple colorectal cancer. Among 99 cases with multiple CRC, 54 indi-
viduals were diagnosed with SCRC and 45 patients with MCRC. In both groups, the mean age at onset was 
around 70 years old, with a male to female ratio > 1. Moreover, the most common tumor location for both groups 
was the entire colon, defined as the location of the synchronous or metachronous tumors at different sides of 
the colon. Only one patient in the SRCR group (1.8%) had MSI in both tumors whereas discordant MSI status 
was found between synchronous tumors in 3 cases (5.6%), of which 1 (25.0%) case was diagnosed with LS. Five 
Figure 3. (A) Sample with CpG Island Methylator Phenotype negative (CIMP−). (B) Sample with CpG Island 
Methylator Phenotype positive (CIMP+).
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(10.4%) and 31 (64.6%) patients presented BRAF mutations and KRAS mutations in at least one tumor, respec-
tively. In the MCRC group, several remarkable features were the diagnosis of metachronous neoplasm at an early 
stage (82.2%), the total concordance of MSI status between paired tumors, and only 1 (2.2%) patient who was 
identified as a LS case, showed MSI status. Regarding a BRAF mutation, MCRC patients showed concordance 
between both tumors, of which 1 (2.2%) patient presented a BRAF mutation. Eighteen (40.0%) MCRC patients 
showed a KRAS mutation in at least one tumor and 11 (24.4%) in paired-tumors (Tables 3 and 4).
CIMp analysis. We analyzed CIMP status in the four subtypes of CRCs patients. The number of methylated 
genes in each tumor of the patients of the different subgroups is shown in Fig. 4. In the cohort of 59 patients with 
EOCRC, 50 (84.7%) tumors were CIMP-(−) and 9 (15.2%) were CIMP-(+). In the 71 patients with LOCRC, 52 
(73.2%) tumors were CIMP-(−) and 19 (26.8%) tumors were CIMP-(+) (Tables 1 and 2). Interestingly, the subset 
of 54 diagnosed individuals with SCRC showed 20 (37.0%) patients with CIMP-(+) tumors and 19 (35.2%) with 
CIMP-(−) tumors, where both tumors presented same CIMP status, and 15 (27.8%) patients with CIMP-MM 
tumors. In the cohort of 45 patients with MCRC, 11 (24.4%) were CIMP-(+) for both tumors, 16 (35.6%) were 
CIMP-(−) for paired tumors, and 18 (40.0%) showed CIMP-MM: 9 (20.0%) were first tumor CIMP-(+) and 
Total
Tumor CIMP-
(−)
Tumor CIMP-
(+) p-valuea
No. of patients 59 (100.0) 50 (84.7) 9 (15.2) —
Average age of onset 40 [5] 40 [5] 39 [5] NSb
Sex
Female 23 (39.0) 19 (62.0) 4 (44.4) NS
Male 36 (61.0) 31 (38.0) 5 (55.6)
Location
Proximal colon 11 (18.6) 6 (12.0) 5 (55.6) 0.008
Distal colon 28 (47.5) 26 (52.0) 2 (22.2)
Rectum 20 (33.9) 18 (36.0) 2 (22.2)
Tumor histology
Adenocarcinoma 47 (79.7) 40 (80.0) 7 (77.8) NS
Adenoma with HGD 12 (20.3) 10 (20.0) 2 (22.2)
Tumor stage
I 16 (27.2) 13 (26.0) 3 (33.3) NS
II 23 (39.0) 19 (38.0) 4 (44.4)
III 10 (16.9) 9 (18.0) 1 (11.1)
IV 10 (16.9) 9 (18.0) 1 (11.1)
Tumor differentiation
Well differentiated 18 (38.3) 17 (41.5) 1 (16.7) NS
Moderately differentiated 24 (51.1) 21 (51.2) 3 (50.0)
Poorly differentiated 5 (10.6) 3 (7.3) 2 (33.3)
Mucin production Tumor 15 (31.9) 12 (29.3) 3 (50.0) NS
“Signet ring” cells Tumor 3 (7.3) 3 (7.3) — NS
Microsatellite status
MSS 51 (86.4) 43 (86.0) 8 (88.9) NS
MSI 8 (13.6) 7 (14.0) 1 (11.1)
BRAF
Wild type 58 (98.3) 49 (98.0) 9 (100.0) NS
Mutated 1 (1.7) 1 (2.0) —
KRAS
Wild type 32 (59.3) 27 (58.7) 5 (62.5) NS
Mutated 22 (40.7) 19 (41.3) 3 (37.5)
Familial cancer history
Sporadic 31 (52.5) 26 (52.0) 5 (55.6) NS
Familial aggregation 23 (39.0) 20 (40.0) 3 (33.3)
HNPCC 5 (8.5) 4 (8.0) 1 (11.1)
Table 1. Clinical variables of interest and CIMP status in the EOCRC. aStatistical comparison was performed 
using Pearson’s Chi Square test (χ2). bStatistical comparison was performed using Student’s t-test. Parenthesis 
refer to percentage numbers. Brackets are used to identify standard deviation. Percentages come from 
different initial number of patients because some cases were excluded: when only one biopsy was available or 
in cases of carcinoma in situ with severe dysplasia in which other features could not be studied. CIMP: CpG 
island methylator phenotype. No. Number. HGD: High-grade dysplasia. MSI: Microsatellite instability. MSS: 
Microsatellite stability. HNPCC: Hereditary non-polyposis colorectal cancer. NS: Not significant.
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second tumor CIMP-(−), and 9 (20.0%) were first tumor CIMP-(−) and second tumor CIMP-(+) (Tables 3 and 
4). Furthermore, the concordance of CIMP status between paired tumors in the SCRC and MCRC groups is sum-
marized in Tables 5 and 6. Thirty-nine (72.2%) SCRC patients showed the same CIMP status in both tumors. In 
the cohort of MCRC, 27 (60%) patients presented concordant CIMP status in both tumors.
Correlation between CIMP phenotype and clinical features. Regarding clinical correlation with CIMP 
status, CIMP-(+) tumors in the EOCRC group were mainly located in proximal colon (p = 0.008), with a very low rate 
of well-differentiated tumors (Table 1). The CIMP-(+) tumors of patients with LOCRC presented moderate tumor dif-
ferentiation (p = 0.045), MSI status (p = 0.021) and a higher BRAF mutation rate (p = 0.001) (Table 2). Other interesting 
features were the higher proportion of females as well as the rectal tumor location (both 63%). In the SCRC subgroup 
(Table 3), cases with both tumors CIMP-(+), 16 (80.0%) patients were male and 11 (55.0%) tumors were distal-sided 
both paired tumors. Most patients diagnosed with MCRC and CIMP-(+) for both tumors showed entire colon location 
(81.8%), mucin production in the first tumor (25%) and early stage at diagnosis of the second tumor (72.7%) (Table 4). 
Differences in diagnostic tumor stage, sex, age and other clinicopathological features analyzed between different and 
concordant CIMP status in the SCRC and MCRC groups were not statistically significant (Tables 3 and 4).
Total
Tumor CIMP-
(−)
Tumor CIMP-
(+) p-valuea
No. of patients 71 (100.0) 52 (73.2) 19 (26.8) NSb
Average age of onset 78 [6] 78 [6] 79 [5] NS
Sex
Female 38 (53.5) 26 (50.0) 12 (63.2) NS
Male 33 (46.5) 26 (50.0) 7 (36.8)
Location
Proximal colon 28 (39.4) 22 (42.3) 6 (31.6) NS
Distal colon 13 (18.3) 12 (23.1) 1 (5.3)
Rectum 30 (42.3) 18 (34.6) 12 (63.2)
Tumor histology
Adenocarcinoma 71 (100.0) 52 (100.0) 19 (100.0) NS
Adenoma with HGD — — —
Tumor stage
I 3 (4.3) 3 (6.0) — NS
II 34 (49.3) 24 (48.0) 10 (52.6)
III 18 (26.1) 15 (30.0) 3 (15.8)
IV 14 (20.3) 8 (16.0) 6 (31.6)
Tumor differentiation
Well differentiated 16 (24.2) 15 (30.6) 1 (5.9) 0.045
Moderately differentiated 47 (71.2) 33 (67.4) 14 (82.4)
Poorly differentiated 3 (4.6) 1 (2.0) 2 (11.8)
Mucin production Tumor 11 (16.7) 9 (18.4) 2 (11.8) NS
“Signet ring” cells Tumor 2 (3.0) 2 (4.1) — NS
Microsatellite status
MSS 65 (91.5) 50 (96.2) 15 (78.9) 0.021
MSI 6 (8.5) 2 (3.8) 4 (21.1)
BRAF
Wild type 65 (91.5) 51 (98.1) 14 (73.7) 0.001
Mutated 6 (8.5) 1 (1.9) 5 (26.3)
KRAS
Wild type 5 (83.3) 4 (80.0) 1 (100.0) NS
Mutated 1 (16.7) 1 (20.0) —
Familial cancer history
Sporadic 62 (91.2) 45 (90.0) 17 (94.4) NS
Familial aggregation 6 (8.8) 5 (10.0) 1 (5.6)
HNPCC 3 (4.4) 2 (4) 1 (5.6)
Table 2. Clinical variables of interest and CIMP status in the LOCRC subgroup. aStatistical comparison was 
performed using Pearson’s Chi Square test (χ2). bStatistical comparison was performed using Student’s t-test. 
Parenthesis refer to percentage numbers. Brackets are used to identify standard deviation. Percentages come 
from different initial number of patients because some cases were excluded: when only one biopsy was available 
or in cases of carcinoma in situ with severe dysplasia in which other features could not be studied. CIMP: CpG 
island methylator phenotype. No.: Number. HGD: High-grade dysplasia. MSI: Microsatellite instability. MSS: 
Microsatellite stability. HNPCC: Hereditary non-polyposis colorectal cancer. NS: Not significant.
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Discussion
CpG-island methylation testing has been proposed as a tool for cancer detection and prognosis, and indicates 
that methylation status is of clinical relevance29, despite the timing of its occurrence and its interaction with other 
genetic defects are not fully understood30–32. In this study, we assessed CIMP status in different subsets of CRCs 
according to age of onset and the number of primary neoplasms: EOCRC and LOCRC with “unique” CRCs, and 
SCRC and MCRC.
In the assessment of CIMP status11,33, we found that only 15.2% of EOCRC patients and 26.8% of LOCRC 
patients showed CIMP-(+) tumors. However, 37.0% of SCRC patients were CIMP-(+) for both tumors and 
Total
Tumor A 
CIMP-(−)
Tumor A 
CIMP-(+) Tumor A
p-valuea
Tumor B 
CIMP-(−)
Tumor B 
CIMP-(+)
Tumor B 
CIMP-(MM)
No. of patients 54 (100.0) 19 (35.2) 20 (37.0) 15 (27.8) —
Average age of onset 70 [10] 72 [10] 67 [11] 71 [10] NSb
Sex
Female 18 (33.3) 9 (47.4) 4 (20.0) 5 (33.3) NS
Male 36 (66.7) 10 (52.6) 16 (80.0) 10 (66.7)
Location
Proximal colon 7 (13.0) 3 (15.8) 1 (5.0) 3 (20.0) NS
Distal colon 21 (38.9) 6 (31.6) 11 (55.0) 4 (26.7)
Entire colon 26 (48.1) 10 (52.6) 8 (40.0) 8 (53.3)
Tumor histology
Adenocarcinoma 44 (81.5) 14 (73.7) 17 (85.0) 13 (86.7) NS
Adenoma with HGD 10 (18.5) 5 (26.3) 3 (15.0) 2 (13.3)
Tumor stage
I 24 (44.4) 9 (47.4) 7 (35.0) 8 (53.3) NS
II 17 (31.5) 8 (42.1) 5 (25.0) 4 (26.7)
III 10 (18.5) 2 (10.5) 6 (30.0) 2 13.3)
IV 3 (5.6) — 2 (10.0) 1 (6.7)
Tumor differentiation
Well differentiated 23 (52.3) 10 (71.4) 7 (41.2) 6 (46.2) NS
Moderately differentiated 18 (40.9) 4 (28.6) 9 (52.9) 5 (38.5)
Poorly differentiated 3 (6.8) — 1 (5.9) 2 (15.4)
Mucin production Tumor 10 (23.3) 4 (28.6) 2 (12.5) 4 (30.8) NS
“Signet ring” cells Tumor 2 (4.6) 1 (7.1) — 1 (7.7) NS
Microsatellite status
MSS 50 (92.6) 17 (89.5) 20 (100.0) 13 (86.7) NS
MSI 1 (1.8) 1 (5.3) — —
MSS & MSI 3 (5.6) 1 (5.3) — 2 (13.3)
BRAF
Wild type 43 (89.6) 14 (87.5) 17 (94.4) 12 (58.7) NS
Mutated 1 (2.1) — — 1 (7.1)
Wild type & Mutated 4 (8.3) 2 (12.5) 1 (5.6) 1 (7.1)
KRAS
Wild type 17 (35.4) 4 (25.0) 7 (39.8) 6 (42.9) NS
Mutated 12 (25.0) 6 (37.5) 3 (16.7) 3 (21.4)
Wild type & Mutated 19 (39.6) 6 (37.5) 8 (44.4) 5 (35.7)
Familial Cancer History
Sporadic 44 (81.5) 15 (78.9) 16 (80.0) 13 (86.6) NS
Familial aggregation 9 (16.7) 4 (21.1) 4 (20.0) 1 (6.7)
HNPCC 1 (1.8) — — 1 (6.7)
Table 3. Clinical variables of interest and CIMP status in the SCRC subgroup. aStatistical comparison was 
performed using Pearson’s Chi Square test (χ2). bStatistical comparison was performed using analysis of 
variance (ANOVA). Parenthesis refer to percentage numbers. Brackets are used to identify standard deviation. 
Percentages come from different initial number of patients because some cases were excluded: when only 
one biopsy was available or in cases of carcinoma in situ with severe dysplasia in which other features could 
not be studied. CIMP: CpG island methylator phenotype. No.: Number. HGD: High-grade dysplasia. MSI: 
Microsatellite instability. MSS: Microsatellite stability. HNPCC: Hereditary non-polyposis colorectal cancer. NS: 
Not significant.
8Scientific RepoRts |         (2019) 9:10516  | https://doi.org/10.1038/s41598-019-47014-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Total
1st Tumor CIMP-(−) 2nd 
Tumor CIMP-(−)
1st Tumor CIMP-(−) 2nd 
Tumor CIMP-(+)
1st Tumor CIMP-(+) 2nd 
Tumor CIMP-(−)
1st Tumor CIMP-(+) 2nd 
Tumor CIMP-(+) p-valuea
No. of patients 45 (100.0) 16 (35.6) 9 (20.0) 9 (20.0) 11 (24.4) —
Average age of onset
1st Tumor 69 [8] 71 [8] 68 [12] 66 [8] 66 [5] NSb
2nd Tumor 72 [8] 74 [7.9] 71 [12.5] 70 [7] 70 [5.5] NSb
Sex
Female 16 (35.6) 5 (31.2) 6 (66.7) 3 (33.3) 2 (18.2) NS
Male 29 (64.4) 11 (68.8) 3 (33.3) 6 (66.7) 9 (81.8)
Location
Proximal colon 5 (11.1) 2 (12.5) 1 (11.1) 1 (11.1) 1 (9.1) NS
Distal colon 10 (22.2) 6 (37.5) 2 (22.2) 1 (11.1) 1 (9.1)
Entire colon 30 (66.7) 8 (50.0) 6 (66.7) 7 (77.8) 9 (81.8)
1st Tumor histology
Adenocarcinoma 28 (62.2) 10 (62.5) 4 (44.4) 8 (88.9) 6 (54.5) NS
Adenoma with HGD 17 (37.8) 6 (37.5) 5 (55.6) 1 (11.1) 5 (45.5)
1st Tumor stage
0 16 (35.6) 6 (37.5) 5 (55.6) 1 (11.1) 4 (36.4) NS
I 3 (6.7) 1 (6.3) — — 2 (18.2)
II 13 (28.8) 3 (18.8) 3 (33.3) 6 (66.7) 1 (9.1)
III 10 (22.2) 4 (25.0) 1 (11.1) 1 (11.1) 4 (36.4)
IV 3 (6.7) 2 (12.5) — 1 (11.1) —
1st Tumor differentiation
Well differentiated 30 (83.3) 11 (91.7) 6 (85.7) 6 (66.7) 7 (87.5) NS
Moderately differentiated 6 (16.7) 1 (8.3) 1 (14.3) 3 (33.3) 1 (12.5)
Poorly differentiated — — — — —
Mucin production 1st Tumor 3 (10.3) 1 (8.3) — 1 (11.1) 2 (25.0) NS
“Signet ring” cells 1st Tumor 1 (3.8) — — 1 (11.1) — NS
2nd Tumor histology
Adenocarcinoma 8 (17.8) — 2 (22.2) 2 (22.2) 4 (36.4) NS
Adenoma with HGD 37 (82.2) 16 (100) 7 (77.8) 7 (77.8) 7 (63.6)
2nd Tumor stage
0 35 (77.8) 14 (87.5) 7 (77.8) 7 (77.8) 7 (63.6) NS
I 2 (4.4) 1 (6.3) — — 1 (9.1)
II 7 (15.6) 1 (6.3) 2 (22.2) 2 (22.2) 2 (18.2)
III 1 (2.2) — — — 1 (9.1)
IV — — — — —
2nd Tumor differentiation
Well differentiated 14 (77.8) 5 (100.0) 3 (75.0) 1 (50.0) 5 (71.4) NS
Moderately differentiated 3 (16.6) — — 1 (50.0) 2 (28.6)
Poorly differentiated 1 (5.6) — 1 (25.0) — —
Mucin production 2nd Tumor 2 (13.3) — — 1 (25.0) 1 (14.3) NS
“Signet ring” cells 2nd Tumor — — — — — —
Microsatellite status
MSS 44 (97.8) 16 (100) 9 (100) 9 (100) 10 (90.9) NS
MSI 1 (2.2) — — — 1 (9.1)
BRAF
Wild type 44 (97.8) 16 (100) 8 (88.9) 9 (100) 11 (100) NS
Mutated 1 (2.2) — 1 (11.1) — —
KRAS
Wild type 16 (35.6) 7 (43.8) 3 (33.3) 4 (44.4) 2 (18.2) NS
Mutated 11 (24.4) 1 (6.2) 3 (33.3) 3 (33.3) 4 (36.4)
Wild type & Mutated 18 (40.0) 8 (50.0) 3 (33.3) 2 (22.2) 5 (45.5)
Familial Cancer history
Sporadic 35 (77.8) 12 (75.0) 5 (55.6) 8 (88.9) 10 (90.9) NS
Familial aggregation 9 (20.0) 4 (25.0) 4 (44.4) 1 (11.1) —
HNPCC 1 (2.2) — — — 1 (9.1)
Table 4. Clinical variables of interest and CIMP status in the MCRC subgroup. aStatistical comparison was 
performed using Pearson’s Chi Square test (χ2). bStatistical comparison was performed using analysis of variance 
(ANOVA). Parenthesis refer to percentage numbers. Brackets are used to identify standard deviation. Percentages 
come from different initial number of patients because some cases were excluded: when only one biopsy was 
available or in cases of carcinoma in situ with severe dysplasia in which other features could not be studied. CIMP: 
CpG island methylator phenotype. No.: Number. HGD: High-grade dysplasia. MSI: Microsatellite instability. MSS: 
Microsatellite stability. HNPCC: Hereditary non-polyposis colorectal cancer. NS: Not significant.
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27.8% of the tumor pairs showed at least one CIMP-(+) tumor, suggesting that the serrated pathway of carcino-
genesis could be the main mechanism for SCRC development34,35. In the MCRC group, 24.4% were CIMP-(+) for 
both tumors and 40.0% were CIMP-(+) for at least one tumor. The reported differences in CIMP-(+) frequency 
between different groups could reflect the relative involvement of this particular molecular phenotype throughout 
the development of multiple neoplasms. In summary, our findings show a higher CIMP-(+) frequency in patients 
who develop multiple tumors than in patients who develop a single tumor. These different epigenetic patterns 
may be due to a “field effect” and possibly a highly-susceptible tissue microenvironment could be generated by 
the interplay of different etiologic factors including lifestyle, eating habits or environmental issues leading to the 
appearance and development of malignant tumors20,36.
Moreover, in this study we observed that most pairs of tumors had concordant CIMP status in patients with 
SCRC (72.2%) which suggests that CIMP is maintained throughout neoplasm development; this has been taken 
as a evidence for the high probability that synchronous tumors could be developed through the same genetic 
pathway in each particular patient37. On the other hand, 40% of the patients diagnosed with MCRC did not 
present concordance concerning CIMP status. The clinical implication of this finding is that the analysis of the 
CIMP status in any of the synchronous tumors could provide a reasonably reliable prediction of CIMP status in 
the other tumors even when it is not directly assayed. However, this prediction would be less reliable in MCRC. 
Comparison of these epigenetic patterns in synchronous and metachronous lesions may suggest that there is a 
tendency to have clonal features or a stronger “field effect” in patients diagnosed with SCRC, while the tumor 
heterogeneity in patients with MCRC may be caused by the contribution of different carcinogenic pathways in 
tumors developed at different time points.
About the results from the correlation between CIMP status and the clinical features within each group of 
tumors, recent systematic reviews have confirmed the association between CIMP phenotype and older ages, 
female gender, proximal tumor location, mucinous histology, poor differentiation and MSI36,37. According to the 
“unique” colorectal cancers, EOCRC subset showed the proximal location, mucinous and poorly-differentiated 
Figure 4. Number of methylated genes in each tumor of (a) EOCRC patients; (b) LOCRC patients; (c) SCRC 
patients; (d) MCRC patients.
CIMP status Tumor B (+) Tumor B (−)
Tumor A (+) 20 (37.0%) 1 (1.9%)
Tumor A (−) 14 (25.9%) 19 (35.2%)
Table 5. Concordance of CIMP status in paired-tumors from patients diagnosed with SCRC using eight-
marker panel. CIMP: CpG island methylator phenotype. SCRCs: Synchronous colorectal cancer.
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phenotype, while LOCRC linked with a higher proportion within this subset, and gender and MSI phenotype. 
Maybe the age-of-onset criterion gives rise to this stratification in the characteristics related to the CIMP in this 
type of CRC. Nevertheless, this characteristics didn´t correlate with Multiple Primary CRCs.
Our results seem to confirm the fact that there are distinct groups of CRC patients. This study, focused on the 
current knowledge of epigenetic alterations in CRC, could represent a substantial contribution to this research 
line, since it may have implications in terms of prevention, diagnosis and therapy.
Conclusion
Our results underscore the importance of taking into account several criteria for the development of multiple 
primary tumors when analyzing CRC. There is higher CIMP-(+) frequency in patients diagnosed with multiple 
CRC than in patients with “unique” CRC. Additionally, we conclude that there is a concordance of CIMP status 
of synchronous tumors in SCRC. Therefore, it could be suggested that CIMP status in one of the simultaneous 
tumors could predict CIMP status of other tumors.
Data Availability
The data that support the findings of this study are available from the corresponding author on reasonable request.
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